μ₯νΈλ μ€νμ΄λ
μ₯νΈλ μ€νμ΄λλ **μλ§ν μ€νν΄ μ μ¬μ²΄**λ‘ μμνμμ μ£Όλ‘ μ·μ₯ λ΄λΆλΉ μ’ μ(**μΈμλ¦°μ’ **, **κ°μ€νΈλ¦°μ’ ** λ±) λ° **λ§λ¨λΉλμ¦** κ΄λ¦¬μ μ¬μ©λ©λλ€. > **μμ κ²½κ³ **: μ°κ΅¬μ λ°λ₯΄λ©΄ μ₯νΈλ μ€νμ΄λλ λλΆλΆμ μΈμλ¦°μ’ μ μ μ©νμ§ μμ΅λλ€. μλ§ν μ€νν΄ μμ©μ²΄λ₯Ό λ°ννμ§ μλ μ’ μμ μΉλ£μ λ°μνμ§ μμ΅λλ€. **μμ ν**: λ§λ¨λΉλμ¦ μΉλ£μ μ¬μ©λμ΄ μμΌλ, νμλ μ€νμ΄λμ κ°μ μλ‘μ΄ μλ§ν μ€νν΄ μ μ¬μ²΄κ° μΉλ£μ λ μ λ§ν κ²μΌλ‘ 보μ λλ€(λ¨, νμ¬λ κ³ κ°μ).
μμ© κΈ°μ : Octreotide acts as a synthetic **somatostatin analogue**. It binds to **somatostatin receptors** (SSTRs) β inhibits the release of several hormones, including growth hormone (GH), insulin, glucagon, and gastrin, as well as reducing splanchnic blood flow and gastrointestinal motility.
λλ¬Ό μ’ λ³ μ©λ
- Management of pancreatic endocrine tumours and acromegaly Β· 10-20 ΞΌg/animal or 10 ΞΌg/animal Β· SC Β· q8-12h or q8h Β· As directed Β· Dose is for the aqueous preparation. Dosages for the depot preparation are not known in animals.
- Management of pancreatic endocrine tumours and acromegaly Β· 10-20 ΞΌg/animal or 10 ΞΌg/animal Β· SC Β· q8-12h or q8h Β· As directed Β· Dose is for the aqueous preparation. Dosages for the depot preparation are not known in animals.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Known hypersensitivity to octreotide
μ΄μλ°μ
- Anorexia
- Vomiting
- Abdominal pain
- Bloating
- Diarrhoea
- Steatorrhoea
- Hepatopathy
- Pain at injection sites
λͺ¨λν°λ§
- Blood glucose levels (especially when treating insulinoma)
- Clinical signs of gastrointestinal upset
- Liver enzymes (due to potential hepatopathy)
- Injection site reactions
κ³Όμ©λ
No specific information available in the monograph. Overdose may exacerbate gastrointestinal disturbances and cause significant fluctuations in blood glucose levels. Treatment should be symptomatic and supportive.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.